TORONTO, May 2, 2019 /CNW/ - Bill Radvak, Executive Chairman, NervGen Pharma Corp. (NGEN), joined Tim Babcock, Managing Director, Capital Formation, TSX Venture Exchange, to open the market. NervGen is a regenerative medicine company dedicated to the advancement of innovative therapeutics for the treatment of nerve damage, including spinal cord injuries and peripheral nerve injuries. NervGen Pharma Corp. commenced trading on TSX Venture Exchange on March 13, 2019.

NervGen Pharma Corp. Opens the Market (CNW Group/TMX Group Limited)

SOURCE TMX Group Limited

Copyright 2019 Canada NewsWire

Nervgen Pharma (TSXV:NGEN)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024 Nervgen Pharma 차트를 더 보려면 여기를 클릭.
Nervgen Pharma (TSXV:NGEN)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024 Nervgen Pharma 차트를 더 보려면 여기를 클릭.